tibulizumab   

GtoPdb Ligand ID: 10350

Synonyms: LY-3090106 | LY3090106
Compound class: Antibody
Comment: Tibulizumab (LY3090106) is an investigational bispecific monoclonal antibody. It is a humanized antibody that simultaneously targets IL-17A and BAFF (TNFSF13B; CD257), that was produced by Eli Lilly as a potential therapeutic for IL-17-driven autoimmune diseases. Peptide sequences for tibulizumab (accessed from IMGT) are 100% matches with SEQ IDs 1 and 2 from patent WO2013158577A1, entitled 'Anti-baff-anti-il-17 bispecific antibodies' [1]. Tibulizumab neutralises IL-17 and BAFF bioactivities in vitro and in vivo [1].
No information available.
Summary of Clinical Use
Tibulizumab (LY3090106) is a Phase 1 clinical candidate for Sjögren's syndrome and rheumatoid arthritis. Click here to link to ClinicalTrials.gov's full list of tibulizumab trials.